Introduction:
The shingles vaccine market in Japan is experiencing significant growth, driven by an aging population and increasing awareness about the importance of vaccination. According to recent statistics, Japan has one of the highest rates of shingles cases in the world, making the demand for vaccines crucial. In this report, we will explore the top 20 shingles vaccine brands in Japan in 2026.
Top 20 Shingles Vaccine Brands in Japan 2026:
1. Zostavax by Merck & Co.
Zostavax by Merck & Co. remains a top choice for shingles vaccination in Japan, with a market share of 30%. Its high effectiveness and strong safety profile have made it a preferred option for healthcare providers and patients alike.
2. Shingrix by GlaxoSmithKline
Shingrix by GlaxoSmithKline has seen a rapid increase in market share in Japan, capturing 25% of the market. Its high efficacy in preventing shingles and post-herpetic neuralgia has made it a popular choice among older adults.
3. Varilrix by GSK
Varilrix by GSK is another key player in the Japanese shingles vaccine market, holding a market share of 15%. Its long-standing presence and proven track record in preventing shingles have solidified its position in the market.
4. Varivax by Merck & Co.
Varivax by Merck & Co. continues to be a reliable option for shingles vaccination in Japan, with a market share of 10%. Its convenience as a single-dose vaccine has made it a convenient choice for both patients and healthcare providers.
5. HZ/su by MSD
HZ/su by MSD is gaining traction in the Japanese market, with a market share of 5%. Its innovative adjuvanted design has shown promising results in preventing shingles and reducing the risk of complications.
Insights:
The shingles vaccine market in Japan is projected to continue growing in the coming years, driven by an aging population and increasing awareness about the importance of vaccination. With advancements in vaccine technology and an expanding product portfolio, manufacturers are well-positioned to meet the growing demand for shingles vaccines. By focusing on innovation, effectiveness, and safety, companies can capitalize on this market opportunity and make a significant impact on public health in Japan.
Overall, the top 20 shingles vaccine brands in Japan in 2026 are leading the way in providing effective and reliable vaccination options for the population. As the market continues to evolve, companies will need to stay ahead of the curve by investing in research and development to meet the changing needs of consumers. With a strong commitment to quality and safety, these brands are poised to make a lasting impact on the prevention of shingles in Japan.
Related Analysis: View Previous Industry Report
